Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

[News]

ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.

More... (http://www.news-medical.net/news/20101206/Preclinical-data-of-ZIO-101-in-various-lymphoma-models-presented-at-ASH-2010.aspx)